Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.
All Authors:
Authors
Sivakumar K, Cochrane TI, Sloth B, Ashar H, Laurent D, Tankó LB, Amato AA.
Author Profiles:
Persons
Publish Date:
Date
Journal:
Venue / Journal
Neurology
Additional Journal Information
95(14):e1971-e1978